Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS

Observational Sutdy to Assess the Effectiveness of Avodart in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00316732

Enrollment

173

Registered

2006-04-21

Start date

2004-10-25

Completion date

2006-12-19

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Keywords

Avodart, IPSS, BPH, dutasteride, EQ-5D, Observational

Brief summary

This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.

Interventions

PROCEDUREIPSS Questionnaire

PROCEDUREEQ-5D Questionnaire

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia). * Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH. * Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.

Exclusion criteria

None specified

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026